Integrated Filing — IndAS


General information about company

Scrip Code 543524
NSE Symbol RAINBOW
MSEI Symbol NOTLISTED
ISIN INE961O01016
Name of company Rainbow Childrens Medicare Limited
Type of company Main Board
Class of security Equity
Date of start of financial year 01-Apr-2024
Date of end of financial year 31-Mar-2025
Date of board meeting when results were approved 24-May-2025
Date on which prior intimation of the meeting for considering financial results was informed to the exchange 17-May-2025
Description of presentation currency INR (in Actuals)
Reporting Type Quarterly
Reporting Quarter Fourth quarter
Nature of report standalone or consolidated Consolidated
Whether results are audited or unaudited for the quarter ended Audited
Whether results are audited or unaudited for the Year to date for current period ended/year ended Audited
Segment Reporting Single segment
Description of single segment The business of running multi specialty pediatric and obstetrics and gynecology hospital.
Start date and time of board meeting 24-May-2025   15:00:00
End date and time of board meeting 24-May-2025   18:00:00
Whether cash flow statement is applicable on company Yes
Type of cash flow statement Cash Flow Indirect
Declaration of unmodified opinion or statement on impact of audit qualification Declaration of unmodified opinion



Financial Results Ind-AS

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-Jan-2025 01-Apr-2024
B Date of end of reporting period 31-Mar-2025 31-Mar-2025
C Whether results are audited or unaudited Audited Audited
D Nature of report standalone or consolidated Consolidated Consolidated
Part I Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.
1 Income
Revenue from operations 3701070000 15158660000
Other income 145270000 510080000
Total income 3846340000 15668740000
2 Expenses
(a) Cost of materials consumed 470410000 1949200000
(b) Purchases of stock-in-trade 0 0
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade 0 0
(d) Employee benefit expense 543160000 2063670000
(e) Finance costs 181210000 724550000
(f) Depreciation, depletion and amortisation expense 341630000 1384400000
(f) Other Expenses
1 Professional Fees to Doctors 944610000 3690210000
2 Canteen expenses 58670000 271050000
3 Contract wages 109500000 400660000
4 Housekeeping expenses 20480000 82270000
5 Power and fuel 61580000 277210000
6 Lab and investigations 39840000 171990000
7 Repairs and maintenance 84650000 327680000
8 Rates and taxes 44540000 168390000
9 Business promotion and advertisement 53670000 309440000
10 Other Expenses 122700000 548010000
Total other expenses 1540240000 6246910000
Total expenses 3076650000 12368730000
3 Total profit before exceptional items and tax 769690000 3300010000
4 Exceptional items 0 0
5 Total profit before tax 769690000 3300010000
6 Tax expense
7 Current tax 197810000 892930000
8 Deferred tax 6350000 -35190000
9 Total tax expenses 204160000 857740000
10 Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement 0 0
11 Net Profit Loss for the period from continuing operations 565530000 2442270000
12 Profit (loss) from discontinued operations before tax 0 0
13 Tax expense of discontinued operations 0 0
14 Net profit (loss) from discontinued operation after tax 0 0
15 Share of profit (loss) of associates and joint ventures accounted for using equity method 0 0
16 Total profit (loss) for period 565530000 2442270000
17 Other comprehensive income net of taxes 30050000 -610000
18 Total Comprehensive Income for the period 595580000 2441660000
19 Total profit or loss, attributable to
Profit or loss, attributable to owners of parent 563350000 2434240000
Total profit or loss, attributable to non-controlling interests 2180000 2180000
20 Total Comprehensive income for the period attributable to
Comprehensive income for the period attributable to owners of parent 593190000 2433410000
Total comprehensive income for the period attributable to owners of parent non-controlling interests 2390000 8250000
21 Details of equity share capital
Paid-up equity share capital 1015520000 1015520000
Face value of equity share capital 10 10
27 Details of debt securities
22 Reserves excluding revaluation reserve 13666410000
23 Earnings per share
i Earnings per equity share for continuing operations
Basic earnings (loss) per share from continuing operations 5.55 23.97
Diluted earnings (loss) per share from continuing operations 5.55 23.84
ii Earnings per equity share for discontinued operations
Basic earnings (loss) per share from discontinued operations 0 0
Diluted earnings (loss) per share from discontinued operations 0 0
ii Earnings per equity share
Basic earnings (loss) per share from continuing and discontinued operations 5.55 23.97
Diluted earnings (loss) per share from continuing and discontinued operations 5.55 23.84
24 Debt equity ratio
25 Debt service coverage ratio
26 Interest service coverage ratio
27 Disclosure of notes on financial results Notes n n1. The above statement of audited consolidated financial results of Rainbow Childrens Medicare Limited the Company and its subsidiaries the Company and its subsidiaries together referred to as the Group which have been prepared in accordance with Indian Accounting Standards Ind AS prescribed under section 133 of Companies Act 2013 the Act read with relevant rules issued thereunder other accounting principles generally accepted in India and guidelines issued by the Securities and Exchange Board of India SEBI were reviewed and recommended by the Audit Committee and approved by the Board of Directors at their respective meetings held on 24 May 2025. The statutory auditors have expressed an unmodified audit opinion on these results. nttttt n2. The consolidated figures for the fourth quarter ended 31 March 2025 are the balancing figures between published audited figures in respect of the full previous financial year and the published unaudited year to date figures up to the third quarter of the relevant financial year. Also the figures up to the end of third quarter were only reviewed and not subjected to audit. tttt nt n3. The Board of Directors of the Company on 24 May 2025 recommended dividend for the financial year 2024 25 Rs.3 per Equity Share of Rs.10 each aggregating to Rs. 304.66 million. The payment is subject to approval of the shareholders at the ensuing Annual General Meeting of the Company.ttt n n4. Refer Results Pdf.ttttt n n5. Pursuant to the resolutions passed by the Board of Directors on 09 February 2025 and by the Shareholders on 02 April 2025 the Company approved The Rainbow Childrens Medicare Limited Employee Stock Option Scheme 2025 ESOP 2025 in compliance with the SEBI Share Based Employee Benefits and Sweat Equity Regulations 2021 SEBI SBEB SE Regulations. The ESOP 2025 scheme is for issue of employee stock options to eligible employees which may result in an issuance of a maximum number of 1015000 Equity Shares. Upon exercise and payment of the exercise price an option holder will be entitled to be allotted one Equity Share per employee stock option. The exercise price per option shall be determined by the Nomination and Remuneration Committee subject to a maximum discount of up to 20% from the market price of shares as on the date of grant.t ntttt n6.The Group is principally engaged in a single business segment viz. rendering medical and healthcare services. Further the business operation of the group are concentrated in India and hence the group is considered to operate only in one geographical segment.ttttt n7.The consolidated financial results for the quarter and year ended 31 March 2025 are available on the BSE Limited website URL www.bseindia.com the National Stock Exchange of India Limited website URL www.nseindia.com and on the Companys website URL www.rainbowhospitals.in.ttttt n8.The audited consolidated financial results include the financial results of Rainbow Childrens Medicare Limited and the financial results of its subsidiaries Rainbow C R O Private Limited Rainbow Fertility Private Limited Rainbow Women Childrens Hospital Private Limited Rainbow Speciality Hospitals Private Limited Rosewalk Healthcare Private Limited Rainbow Childrens Hospital Private Limited and its other consolidating entity Rainbow Childrens Hospital Foundation. n



Remarks

Debt equity ratio
Debt service coverage ratio
Interest service coverage ratio


Statement of Asset and Liabilities

Particulars Year ended (dd-mm-yyyy)
Date of start of reporting period 01-Apr-2024
Date of end of reporting period 31-Mar-2025
Whether results are audited or unaudited Audited
Nature of report standalone or consolidated Consolidated
Assets
1 Non-current assets
Property, plant and equipment 13878150000
Capital work-in-progress 277660000
Investment property 0
Goodwill 0
Other intangible assets 103280000
Intangible assets under development 6930000
Biological assets other than bearer plants 0
Investments accounted for using equity method 0
Non-current financial assets
Non-current investments 30000
Trade receivables, non-current 0
Loans, non-current 297720000
Other non-current financial assets 319740000
Total non-current financial assets 617490000
Deferred tax assets (net) 295890000
Other non-current assets 266250000
Total non-current assets 15445650000
2 Current assets
Inventories 275690000
Current financial asset
Current investments 5707280000
Trade receivables, current 773010000
Cash and cash equivalents 202550000
Bank balance other than cash and cash equivalents 200000
Loans, current 30000000
Other current financial assets 1054700000
Total current financial assets 7767740000
Current tax assets (net) 103680000
Other current assets 177100000
Total current assets 8324210000
3 Non-current assets classified as held for sale 0
4 Regulatory deferral account debit balances and related deferred tax Assets 0
Total assets 23769860000
Equity and liabilities
1 Equity
Equity attributable to owners of parent
Equity share capital 1015520000
Other equity 13666410000
Total equity attributable to owners of parent 14681930000
Non controlling interest 68170000
Total equity 14750100000
2 Liabilities
Non-current liabilities
Non-current financial liabilities
Borrowings, non-current 0
Trade payables, non-current
(A) Total outstanding dues of micro enterprises and small enterprises 0
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 0
Total Trade payable 0
Other non-current financial liabilities 7416790000
Total non-current financial liabilities 7416790000
Provisions, non-current 97250000
Deferred tax liabilities (net) 0
Deferred government grants, Non-current 0
Other non-current liabilities 0
Total non-current liabilities 7514040000
Current liabilities
Current financial liabilities
Borrowings, current 0
Trade payables, current
(A) Total outstanding dues of micro enterprises and small enterprises 102020000
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 807660000
Total Trade payable 909680000
Other current financial liabilities 397090000
Total current financial liabilities 1306770000
Other current liabilities 131990000
Provisions, current 66960000
Current tax liabilities (Net) 0
Deferred government grants, Current 0
Total current liabilities 1505720000
3 Liabilities directly associated with assets in disposal group classified as held for sale
4 Regulatory deferral account credit balances and related deferred tax liability
Total liabilities 9019760000
Total equity and liabilites 23769860000
Disclosure of notes on assets and liabilities



Format for Reporting Segmenet wise Revenue, Results and Capital Employed along with the company results

Particulars 3 months/ 6 month ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period 01-Jan-2025 01-Apr-2024
Date of end of reporting period 31-Mar-2025 31-Mar-2025
Whether accounts are audited or unaudited Audited Audited
Nature of report standalone or consolidated Consolidated Consolidated
1 Segment Revenue (Income)
(net sale/income from each segment should be disclosed)
Total Segment Revenue
Less: Inter segment revenue
Revenue from operations
2 Segment Result
Profit (+) / Loss (-) before tax and interest from each segment
Total Profit before tax
i. Finance cost
ii. Other Unallocable Expenditure net off Unallocable income
Profit before tax
3 (Segment Asset - Segment Liabilities)
Segment Asset
Total Segment Asset
Un-allocable Assets null null
Net Segment Asset null null
4 Segment Liabilities
Segment Liabilities
Total Segment Liabilities
Un-allocable Liabilities null null
Net Segment Liabilities null null
Disclosure of notes on segments



Other Comprehensive Income

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-Jan-2025 01-Apr-2024
B Date of end of reporting period 31-Mar-2025 31-Mar-2025
C Whether results are audited or unaudited Audited Audited
D Nature of report standalone or consolidated Consolidated Consolidated
Other comprehensive income [Abstract]
1 Amount of items that will not be reclassified to profit and loss
1 Re-measurement (loss)/gain on defined benefit obligation 40090000 -980000
Total Amount of items that will not be reclassified to profit and loss 40090000 -980000
2 Income tax relating to items that will not be reclassified to profit or loss 10040000 -370000
3 Amount of items that will be reclassified to profit and loss
Total Amount of items that will be reclassified to profit and loss
4 Income tax relating to items that will be reclassified to profit or loss 0 0
5 Total Other comprehensive income 30050000 -610000



Cash flow statement, indirect

Particulars Year ended (dd-mm-yyyy)
A Date of start of reporting period 2024-04-01
B Date of end of reporting period 2025-03-31
C Whether results are audited or unaudited Audited
D Nature of report standalone or consolidated Consolidated
Part I Blue color marked fields are non-mandatory.
Statement of cash flows
Cash flows from used in operating activities
Profit before tax 3300010000
Adjustments for reconcile profit (loss)
Adjustments for finance costs 724550000
Adjustments for decrease (increase) in inventories -35910000
Adjustments for decrease (increase) in trade receivables, current -77630000
Adjustments for decrease (increase) in trade receivables, non-current 0
Adjustments for decrease (increase) in other current assets -106420000
Adjustments for decrease (increase) in other non-current assets 0
Adjustments for other financial assets, non-current 0
Adjustments for other financial assets, current 0
Adjustments for other bank balances 0
Adjustments for increase (decrease) in trade payables, current 95460000
Adjustments for increase (decrease) in trade payables, non-current 0
Adjustments for increase (decrease) in other current liabilities 0
Adjustments for increase (decrease) in other non-current liabilities 0
Adjustments for depreciation and amortisation expense 1384400000
Adjustments for impairment loss reversal of impairment loss recognised in profit or loss 0
Adjustments for provisions, current 56380000
Adjustments for provisions, non-current 0
Adjustments for other financial liabilities, current -18580000
Adjustments for other financial liabilities, non-current 0
Adjustments for unrealised foreign exchange losses gains 140000
Adjustments for dividend income 0
Adjustments for interest income 144290000
Adjustments for share-based payments -12710000
Adjustments for fair value losses (gains) -281020000
Adjustments for undistributed profits of associates 0
Other adjustments for which cash effects are investing or financing cash flow -78530000
Other adjustments to reconcile profit (loss) 0
Other adjustments for non-cash items 6660000
Share of profit and loss from partnership firm or association of persons or limited liability partnerships 0
Total adjustments for reconcile profit (loss) 1512500000
Net cash flows from (used in) operations 4812510000
Dividends received 0
Interest paid 0
Interest received 0
Income taxes paid (refund) 855930000
Other inflows (outflows) of cash 0
Net cash flows from (used in) operating activities 3956580000
Cash flows from used in investing activities
Cash flows from losing control of subsidiaries or other businesses 0
Cash flows used in obtaining control of subsidiaries or other businesses 0
Other cash receipts from sales of equity or debt instruments of other entities 0
Other cash payments to acquire equity or debt instruments of other entities 0
Other cash receipts from sales of interests in joint ventures 0
Other cash payments to acquire interests in joint ventures 0
Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships 0
Cash payment for investment in partnership firm or association of persons or limited liability partnerships 0
Proceeds from sales of property, plant and equipment 800000
Purchase of property, plant and equipment 1456700000
Proceeds from sales of investment property 0
Purchase of investment property 0
Proceeds from sales of intangible assets 0
Purchase of intangible assets 0
Proceeds from sales of intangible assets under development 0
Purchase of intangible assets under development 0
Proceeds from sales of goodwill 0
Purchase of goodwill 0
Proceeds from biological assets other than bearer plants 0
Purchase of biological assets other than bearer plants 0
Proceeds from government grants 0
Proceeds from sales of other long-term assets 0
Purchase of other long-term assets 0
Cash advances and loans made to other parties 0
Cash receipts from repayment of advances and loans made to other parties 0
Cash payments for future contracts, forward contracts, option contracts and swap contracts 0
Cash receipts from future contracts, forward contracts, option contracts and swap contracts 0
Dividends received 0
Interest received 221900000
Income taxes paid (refund) 0
Other inflows (outflows) of cash -1443980000
Net cash flows from (used in) investing activities -2677980000
Cash flows from used in financing activities
Proceeds from changes in ownership interests in subsidiaries 0
Payments from changes in ownership interests in subsidiaries 0
Proceeds from issuing shares 500000
Proceeds from issuing other equity instruments 0
Payments to acquire or redeem entity's shares 0
Payments of other equity instruments 0
Proceeds from exercise of stock options 0
Proceeds from issuing debentures notes bonds etc 0
Proceeds from borrowings 0
Repayments of borrowings 0
Payments of lease liabilities 873100000
Dividends paid 304640000
Interest paid 0
Income taxes paid (refund) 0
Other inflows (outflows) of cash 0
Net cash flows from (used in) financing activities -1177240000
Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes 101360000
Effect of exchange rate changes on cash and cash equivalents
Effect of exchange rate changes on cash and cash equivalents 0
Net increase (decrease) in cash and cash equivalents 101360000
Cash and cash equivalents cash flow statement at beginning of period 101190000
Cash and cash equivalents cash flow statement at end of period 202550000







Details of Impact of Audit Qualification

Whether results are audited or unaudited Audited
Declaration of unmodified opinion or statement on impact of audit qualification Declaration of unmodified opinion
Auditor's opinion
Declaration pursuant to Regulation 33 (3) (d) of SEBI (LODR) Regulation, 2015: The company declares that its Statutory Auditor/s have issued an Audit Report with unmodified opinion for the period on Standalone results Yes
Sr No. Audit firm's name Whether the firm holds a valid peer review certificate issued by Peer Review Board of ICAI Certificate valid upto
1 S.R. BATLIBOI & ASSOCIATES LLP Yes 31-Jul-2027


Financial details

Sr. Particulars Audited Figures (as reported before adjusting for qualifications) Adjusted Figures (audited figures after adjusting for qualifications)
1 Turnover / Total income
2 Total Expenditure
3 Net Profit/(Loss)
4 Earnings Per Share
5 Total Assets
6 Total Liabilities
7 Net Worth




Signatories detail

Name of CEO / Managing director
Name of CFO
Name of audit committee chairman
Name of statutory auditor
Name of other signatory, if any, with designation
Place
Date